Biological barriers to drug transport prevent successful accumulation of nanotherapeutics specifically at diseased sites, limiting efficacious responses in disease processes ranging from cancer to inflammation. Although substantial research efforts have aimed to incorporate multiple functionalities and moieties within the overall nanoparticle design, many of these strategies fail to adequately address these barriers. Obstacles, such as nonspecific distribution and inadequate accumulation of therapeutics, remain formidable challenges to drug developers. A reimagining of conventional nanoparticles is needed to successfully negotiate these impediments to drug delivery. Site-specific delivery of therapeutics will remain a distant reality unless nanocarrier design takes into account the majority, if not all, of the biological barriers that a particle encounters upon intravenous administration. By successively addressing each of these barriers, innovative design features can be rationally incorporated that will create a new generation of nanotherapeutics, realizing a paradigmatic shift in nanoparticle-based drug delivery.

/pdf/principles-of-nanoparticle-design-for-overcoming-biological-4c2c5quqtc.pdf

Principles of nanoparticle design for overcoming biological barriers to drug delivery

The intrinsic limits of conventional cancer therapies prompted the development and application of various nanotechnologies for more effective and safer cancer treatment, herein referred to as cancer nanomedicine. Considerable technological success has been achieved in this field, but the main obstacles to nanomedicine becoming a new paradigm in cancer therapy stem from the complexities and heterogeneity of tumour biology, an incomplete understanding of nano-bio interactions and the challenges regarding chemistry, manufacturing and controls required for clinical translation and commercialization. This Review highlights the progress, challenges and opportunities in cancer nanomedicine and discusses novel engineering approaches that capitalize on our growing understanding of tumour biology and nano-bio interactions to develop more effective nanotherapeutics for cancer patients.

/pdf/cancer-nanomedicine-progress-challenges-and-opportunities-3dukbks14n.pdf

Cancer nanomedicine: progress, challenges and opportunities.

Polydopamine and Its Derivative Materials: Synthesis and Promising Applications in Energy, Environmental, and Biomedical Fields

In past two decades poly lactic-co-glycolic acid (PLGA) has been among the most attractive polymeric candidates used to fabricate devices for drug delivery and tissue engineering applications. PLGA is biocompatible and biodegradable, exhibits a wide range of erosion times, has tunable mechanical properties and most importantly, is a FDA approved polymer. In particular, PLGA has been extensively studied for the development of devices for controlled delivery of small molecule drugs, proteins and other macromolecules in commercial use and in research. This manuscript describes the various fabrication techniques for these devices and the factors affecting their degradation and drug release.

/pdf/poly-lactic-co-glycolic-acid-plga-as-biodegradable-1xyztolf10.pdf

Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier

https://cyberleninka.org/article/n/933162.pdf

Hydrogels in drug delivery: progress and challenges

Extracellular vesicles (EVs) are lipid bilayer nanovesicles released from living or apoptotic cells that can transport DNA, RNA, protein, and lipid cargo. EVs play critical roles in cell-cell communication and tissue homeostasis, and have numerous therapeutic uses including serving as carriers for nanodrug delivery. There are multiple ways to load EVs with nanodrugs, such as electroporation, extrusion, and ultrasound. However, these approaches may have limited drug-loading rates, poor EV membrane stability, and high cost for large-scale production. Here, it is shown that apoptotic mesenchymal stem cells (MSCs) can encapsulate exogenously added nanoparticles into apoptotic vesicles (apoVs) with a high loading efficiency. When nano-bortezomib is incorporated into apoVs in culture-expanded apoptotic MSCs, nano-bortezomib-apoVs show a synergistic combination effect of bortezomib and apoVs to ameliorate multiple myeloma (MM) in a mouse model, along with significantly reduced side effects of nano-bortezomib. Moreover, it is shown that Rab7 regulates the nanoparticle encapsulation efficiency in apoptotic MSCs and that activation of Rab7 can increase nanoparticle-apoV production. In this study, a previously unknown mechanism to naturally synthesize nano-bortezomib-apoVs to improve MM therapy is revealed.

Encapsulation of Nano-Bortezomib in Apoptotic Stem Cell-Derived Vesicles for the Treatment of Multiple Myeloma.

Compositions and methods regarding guanidinium functionalized polycarbonates that provide potent antimicrobial activity against multidrug resistant (MDR) bacteria, including Klebsiella pneumoniae (K. pneumoniae) are provided. According to an embodiment, an antimicrobial guanidinium-functionalized polymer is provided that comprises a hydrophobic molecular backbone with cationic guanidinium moieties respectively bound to the hydrophobic molecular backbone via butyl spacer groups. The antimicrobial guanidinium-functionalized polymer self-assembles into a micelle structure with hydrophobic residuals of the antimicrobial guanidinium-functionalized polymer buried inside the micelle structure and the cationic guanidinium moieties exposed on an external surface of the micelle structure to target pathogens.

Antimicrobial polycarbonates for multidrug resistant bacteria

A fluorescent pyrene probe method was applied to measure the critical micelle concentration (CMC) of oligocarbonate-fluorene end-functionalized poly(ethylene glycol) (FmE445Fm) triblock copolymers in water. The CMC decreases with lower temperature and higher values of the hydrophobic block length, m. When analyzed by a closed-assembly micelle model, the estimated energetic parameters find a negative ΔH°mic and small positive ΔS°mic suggestive of enthalpy-driven micellization, which differs from entropy-driven oxyethylene/oxybutylene triblock copolymers and octaethylene glycol-n-alkyl ethers. The enthalpy-driven micellization of FmE445Fm may result from the limited hydration of individual hydrophobic F blocks that leads to few hydrogen-bonded waters released during F block association. The π-π stacking oligocarbonate-fluorene system also observed enthalpy-entropy compensation when compared to a series of published data on diblock and triblock copolymer systems. An anomalously low partition equilibrium constant for m = 15.3 implies a tightly-packed core that excludes pyrene intercalation into the fluorene core. This is discussed along with the possible limited applicability to estimate the CMC and potential model drug molecule insertions into the intercalated micelle core.

Enthalpy-driven micellization of oligocarbonate-fluorene end-functionalized Poly(ethylene glycol)☆.

Large benefits of timely planting

Techniques regarding ionene compositions with antimicrobial functionality are provided For example, one or more embodiments can comprise a monomer, which can comprise a single ionene unit The single ionene unit can comprise a cation distributed along a molecular backbone Also, a hydrophobic functional group can be covalently bonded to the molecular backbone, and the single ionene unit can have antimicrobial functionality

Yi Yan Yang

Papers

Encapsulation of Nano-Bortezomib in Apoptotic Stem Cell-Derived Vesicles for the Treatment of Multiple Myeloma.

Antimicrobial polycarbonates for multidrug resistant bacteria

Enthalpy-driven micellization of oligocarbonate-fluorene end-functionalized Poly(ethylene glycol)☆.

Large benefits of timely planting

Monomer compositions with antimicrobial functionality